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Original article
Population studies conducted 2 decades ago established evi-
dence of a direct and independent relationship of plasma 
homocysteine (Hcy) levels with atherosclerosis-related mor-
bidity and mortality.1,2 These initial studies and subsequent 
clinical observations led to include this thiol-containing 
intermediate metabolite among the emergent cardiovascular 
risk factors, although correction of increased levels of Hcy 
in intervention studies was not associated with evidence of 
benefit on the cardiovascular outcome.3 Circulating Hcy is 
maintained at relatively low levels by ongoing enzymatic 
conversion to either methionine or cysteine,4 but some 
conditions including aging, smoking, decreased folate and 
vitamin B12 levels, renal failure, and rare genetic abnor-
malities are associated with increasing levels.5 Many possi-
ble mechanisms linking Hcy with atherogenesis have been 
suggested including prothrombotic and proinflammatory 
effects, increased oxidative stress, endothelial dysfunction, 
and smooth muscle cell proliferation.5
The metabolic syndrome is identified by a cluster of 
abnormalities in which insulin resistance with related hyper-
insulinemia and visceral adipose tissue play a key pathoge-
netic role.6 Robust evidence indicates that subjects with 
this syndrome are at increased risk of major cardiovascular 
events and death.7,8 Animal studies have shown that insulin 
might affect the activity of enzymes involved in Hcy turno-
ver9 and hyperhomocysteinemia has been suggested as a 
possible additional component of the metabolic syndrome.10 
However, findings of studies that examined the association 
between plasma Hcy and the metabolic syndrome in the 
general population11–13 and in groups of patients with hyper-
tension14–16 were highly inconsistent. Also, and to a greater 
importance, it was not clear whether the possible interac-
tion between Hcy and components of the metabolic syn-
drome might affect the prevalence of cardiovascular events, 
an issue that might be particularly relevant in high-risk 
patients such as those with high blood pressure. Therefore, 
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BACKGROUND
Hyperhomocysteinemia and the metabolic syndrome are established 
cardiovascular risk factors and are frequently associated with hyperten-
sion. The relationship of plasma homocysteine (Hcy) with the metabolic 
syndrome and insulin resistance, however, is debated and studies in 
hypertensive patients are limited. In this study, we have investigated 
the association of Hcy with the metabolic syndrome and cerebro- 
cardiovascular events in hypertension.
METHODS
In 562 essential hypertensive patients who underwent accurate assess-
ment of fasting and postload glucose metabolism, insulin sensitivity, 
and renal function, we measured plasma levels of Hcy, vitamin B12, 
folate, and fibrinogen and assessed the prevalence of the metabolic 
syndrome and of coronary heart and cerebrovascular disease (CVD).
RESULTS
Patients with the metabolic syndrome had significantly higher plasma 
Hcy levels. After correction for covariates, increasing Hcy levels were 
associated with an increasing prevalence of the metabolic syndrome, 
coronary heart disease, and CVD. Plasma Hcy was directly correlated 
with age, waist circumference, fasting glucose, triglyceride, uric acid, 
and fibrinogen levels, and homeostatic model assessment index and 
inversely with creatinine clearance and high-density lipoprotein cho-
lesterol, vitamin B12, and folate levels. Logistic regression analysis 
showed an independent association of Hcy levels with age, male gen-
der, vitamin B12 and folate levels, and the metabolic syndrome. Logistic 
regression indicated also an independent association of Hcy with 
cerebro-cardiovascular disease that was independent of the metabolic 
syndrome.
CONCLUSIONS
Elevated plasma Hcy is associated with the metabolic syndrome in 
hypertensive patients. Prevalence of events increases with increasing 
plasma Hcy levels suggesting a contribution of Hcy to cerebro-cardio-
vascular diseases in these patients.
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the aim of the present study was to investigate the relation-
ship between plasma Hcy levels and the metabolic syndrome 
in a large group of patients with primary hypertension and 




A total of 562 patients (301 males and 261 females; age: 
56 ± 13  years) with mild-to-moderate hypertension, who 
were consecutively referred to the outpatient service of the 
Hypertension Clinic at our University, were included in a 
cross-sectional study. Blood pressure was measured by an 
automated device (Omron M6, OMRON Healthcare Co., 
Kyoto, Japan) after each subject had been supine for 15 min-
utes and the average of 3 readings was recorded.17 Diagnosis 
of hypertension was established in all patients according 
to current guidelines.18 All patients were White, lived in 
North-East of Italy, and were representative of the hyperten-
sive population in this area.19 Patients younger than 18 years 
and older than 80 years and pregnant women were excluded, 
together with patients with history of alcohol abuse, glo-
merular filtration rate of less than 30 ml/min/1.73 m2, use 
of fibrates, niacin, or other types of drugs that could inter-
fere with Hcy levels, and acute illness including recent (less 
than 3 months) acute coronary syndrome, coronary revas-
cularization, stroke, and congestive heart failure. Metabolic 
syndrome was diagnosed according to the American Heart 
Association criteria,20 when 2 or more of the following con-
ditions were associated with hypertension: waist circumfer-
ence of more than 102 cm in men or 88 cm in women, fasting 
plasma glucose of 100 mg/dl or more or use of hypoglyce-
mic drugs, triglycerides of 150 mg/dl or more, and high-
density lipoprotein cholesterol of less than 40 mg/dl in men 
or 50 mg/dl in women. In all patients, causes of secondary 
hypertension were excluded on the basis of extensive clini-
cal and laboratory investigations that included analysis of 
medical records, physical examination, urine analysis, blood 
chemistry, duplicate measurements of 24-hour creatinine 
clearance, plasma active renin and aldosterone, urinary 
cortisol and catecholamines, and renal ultrasound exami-
nation with measurement of renal resistance index. Renal 
angio magnetic resonance imaging/computed tomography 
scan and additional functional tests were performed when 
appropriate.21
One-hundred fifty-eight (28%) of 562 patients had never 
been treated with antihypertensive drugs. The remaining 404 
patients (72%) were treated with drugs that were washed-out 
for a minimum of 2 weeks before the study and all patients 
were closely monitored during the wash-out period. Patients 
taking 2 or more antihypertensive agents were admitted to 
the hospital for the duration of the wash-out and in those 
with blood pressure persistently higher than 180/110 mm 
Hg, alpha-blockers and/or calcium channel blockers were 
given (N = 14). All these patients were already taking cal-
cium channel blockers before inclusion in the study. No 
patients were taking either folate or vitamin B12 oral sup-
plements. Before the study, patients ate a standard diet for 
7 days to keep a sodium intake of 100–150 mmol/day that 
was checked with measurement of sodium excretion in 
24-hour urine collections. Patients were defined as smokers 
if they had smoked for at least 5 years and up to 1 year before 
the study and smoking was quantified by the number of cig-
arettes smoked per day. Alcohol intake was quantified by a 
questionnaire22 as grams/day and patients were defined as 
heavy drinkers when consumption was of 30 g/day or more. 
The study was approved by the local Institutional Review 
Board and informed consent was obtained from all patients.
Assessment of cardiovascular and cerebrovascular damage
Prevalence of coronary heart disease (CHD) (i.e., angina, 
myocardial infarction, coronary revascularization proce-
dure, or coronary angiography showing at least one coro-
nary artery stenosis > 50%) was verified in all patients by 
analysis of clinical records and laboratory tests that included 
electrocardiography, echocardiography and, when appro-
priate, exercise testing, myocardial perfusion scan, and 
coronary angiography.23 Prevalence of ischemic CVD (i.e., 
ischemic stroke, transitory ischemic attack, or carotid arte-
rial disease with ultrasound evidence of a stenosis > 50%) 
was verified in all patients by analysis of clinical records, 
physical examination and, when appropriate, cerebral com-
puterized tomography or magnetic resonance, and cerebral 
angiography.
Laboratory measurements
A sample of venous blood was collected in the morn-
ing between 8:00 and 9:00 AM, after an overnight fast 
with the patients in sitting position. Blood was collected 
into silicone-treated tubes containing trisodium citrate 
and plasma was immediately separated and frozen at 
−80 °C until assaying, usually within 1 month from sam-
pling. Plasma Hcy was determined by a nephelometric 
method (Dimension Vista System, Siemens Healthcare 
Diagnostics, Milan, Italy) with inter- and intra-assay coef-
ficients of variation of 8.2% and 7.0%, respectively, and 
lower limit of detection of 2.0 µmol/l. Total cholesterol and 
triglycerides were assayed enzymatically by an automated 
method. High-density lipoprotein cholesterol was assayed 
enzymatically after magnesium chloride–dextran sulfate 
precipitation of apolipoprotein B-containing lipoproteins 
and low-density lipoprotein cholesterol was calculated 
with the formula of Friedewald. Vitamin B12 and folate 
were measured by standard automated competitive dis-
placement assays. Glomerular filtration rate was measured 
by duplicate measurement of 24-hour creatinine clear-
ance and normalized for body surface area.24 Fibrinogen 
was measured by a functional assay in an automatic 
coagulometer autoanalyzer.25 Plasma glucose was assayed 
using the glucose oxidase method and plasma insulin was 
measured by radioimmunoassay. The homeostatic model 
assessment (HOMA) index was calculated as an index of 
insulin sensitivity from fasting plasma glucose (mmol/l) 
and insulin (µU/ml) using the formula: ((glucose × insu-
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of a 180-minute oral glucose tolerance test (OGTT) and 
the area under the curve for plasma glucose (AUC-G) and 
insulin (AUC-I) concentration during the OGTT was cal-
culated by the trapezoidal rule as described previously.26
Statistical analysis
Values are expressed as mean ± SD for normally distrib-
uted variables, with median and interquartile ranges used 
Table 1. Clinical characteristics and biochemical variables of the study patients grouped according to the presence or absence of the 
metabolic syndrome
All patients (n = 562) Metabolic syndrome (no) (n = 356) Metabolic syndrome (yes) (n = 206) P
Clinical characteristics
 Age, year 56 ± 13 55 ± 14 58 ± 12 0.02
 Males, n (%) 301 (53) 183 (51) 118 (57) <0.01
 Family history of CV disease, n (%) 301 (53) 188 (53) 113 (55) 0.66
 Body mass index, kg/m2 28.4 ± 5.2 26.8 ± 4.4 31.2 ± 5.3 <0.01
 Waist circumference, cm 97 ± 13 92 ± 12 104 ± 12 <0.01
 Heart rate, bpm 72 ± 11 73 ± 11 73 ± 10 0.99
 Systolic blood pressure, mm Hg 147 ± 20 146 ± 21 148 ± 18 0.16
 Diastolic blood pressure, mm Hg 89 ± 12 89 ± 12 89 ± 12 0.51
 Duration of hypertension, year 10.6 ± 9.6 9.8 ± 9.2 12.1 ± 10.1 0.01
 Antihypertensive treatment, n (%) 404 (72) 239 (67) 165 (80) <0.01
 Alcohol, g/day 13 ± 25 11 ± 18 16 ± 34 0.04
 Smokers, n (%) 139 (25) 75 (21) 64 (31) 0.01
 Diabetes, n (%) 91 (16) 28 (8) 63 (30) <0.01
 Coronary heart disease, n (%) 54 (10) 28 (8) 26 (13) 0.06
 Cerebrovascular disease, n (%) 27 (5) 16 (4) 11 (5) 0.65
Biochemical variables
 Creatinine, mg/dl 1.02 ± 0.31 1.00 ± 0.30 1.06 ± 0.34 0.04
 Creatinine clearance, ml/min/1.73 m2 87 ± 27 90 ± 26 84 ± 28 0.03
 Urinary protein excretion, mg/day 90 (65–139) 89 (61–131) 97 (68–156) 0.02
 Glucose, mg/dl 102 ± 30 94 ± 19 116 ± 39 <0.01
 Insulin, µUI/ml 9.1 (6.0–13.0) 7.9 (5.3–10.7) 11.9 (8.5–17.5) <0.01
 HOMA index 2.13 (1.36–3.27) 1.74 (1.20–2.58) 3.11 (2.09–4.94) <0.01
 AUC-G, mg/dl/min 397 ± 107 375 ± 96 442 ± 114 <0.01
 AUC-I, µUI/ml/min 177 (118–289) 158 (103–263) 232 (151–354) <0.01
 Triglycerides, mg/dl 105 (78–148) 91 (70–115) 159 (112–210) <0.01
 Total cholesterol, mg/dl 206 ± 42 203 ± 39 211 ± 47 0.05
 HDL cholesterol, mg/dl 58 ± 16 62 ± 15 50 ± 15 <0.01
 LDL cholesterol, mg/dl 122 ± 37 122 ± 36 124 ± 38 0.59
 Uric acid, mg/dl 5.59 ± 1.51 5.28 ± 1.44 6.14 ± 1.47 <0.01
 Homocysteine, µmol/l 11.9 (9.3–14.7) 11.4 (9.1–14.3) 12.5 (10.1–15.4) 0.01
 Vitamin B12, pg/ml 386 (293–508) 385 (288–495) 387 (299–532) 0.72
 Folate, ng/ml 5.20 (3.60–7.20) 5.0 (3.50–7.14) 5.30 (3.87–7.27) 0.30
 Fibrinogen, mg/dl 356 (311–409) 345 (303–399) 376 (328–420) 0.01
Values are expressed as mean ± SD. Median and interquartile range given in parenthesis under “Biochemical variables” are shown for vari-
ables with skewed distribution. Comparisons between patients with or without the metabolic syndrome were done by the Student’s t-test after 
log transformation for variables with skewed distribution. Pearson’s chi-square test was used to compare frequency distributions. To convert to 
international units, multiply creatinine by 88.4 (µmol/l), glucose by 0.05551 (nmol/l), insulin by 7.175 (pmol/l), cholesterol by 0.0259 (mmol/l), 
triglycerides by 0.0113 (mmol/l), and uric acid by 59.485 (µmol/l).
Abbreviations: AUC-G, area under the curve of plasma glucose after oral glucose tolerance test; AUC-I, area under the curve of plasma 
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for variables with skewed distributions. Normality of dis-
tribution was assessed with the Kolmogorov–Smirnov test, 
and variables with skewed distributions were analyzed after 
logarithmic transformation. The Student’s t-test was used 
for comparison between 2 independent groups. Analysis of 
variance was used for comparisons of more than 2 groups, 
Table 2. Clinical characteristics of the study patients grouped according to quartiles of plasma homocysteine levels
I (n = 143) II (n = 139) III (n = 139) IV (n = 141) P
Clinical characteristics
 Age, year 52 ± 13 54 ± 13 57 ± 14 60 ± 13 <0.01
 Males, n (%) 58 (41) 71 (51) 85 (61) 87 (62) 0.01
 Family history of CV disease, n (%) 76 (53) 67 (48) 71 (51) 87 (62) 0.23
 Body mass index, kg/m2 28.2 ± 5.5 29.0 ± 5.6 28.6 ± 5.0 27.9 ± 4.6 0.31
 Waist circumference, cm 94 ± 14 95 ± 14 98 ± 13 99 ± 11 0.07
 Heart rate, bpm 73 ± 11 73 ± 11 73 ± 12 72 ± 9 0.45
 Systolic blood pressure, mm Hg 146 ± 17 145 ± 18 148 ± 21 149 ± 19 0.27
 Diastolic blood pressure, mm Hg 89 ± 11 90 ± 11 90 ± 12 88 ± 12 0.45
 Duration of hypertension, year 9.9 ± 9.3 10.2 ± 9.1 11.1 ± 9.3 11.5 ± 10.5 0.51
 Antihypertensive treatment, n (%) 89 (62) 104 (75) 107 (77) 104 (74) 0.03
 Alcohol, g/day 12 ± 23 14 ± 34 12 ± 23 14 ± 20 0.86
 Smokers, n (%) 33 (23) 34 (24) 40 (29) 32 (23) 0.63
 Metabolic syndrome, n (%) 37 (26) 53 (38) 56 (40) 60 (42) 0.02
 Coronary heart disease, n (%) 11 (8) 6 (4) 10 (7) 27 (19) <0.01
 Cerebrovascular disease, n (%) 3 (2.1) 6 (4.3) 5 (3.6) 13 (9.2) 0.03
Biochemical variables
 Creatinine, mg/dl 0.92 ± 0.20 0.95 ± 0.19 1.05 ± 0.34 1.17 ± 0.42 <0.01
 Creatinine clearance, ml/min/1.73 m2 102 ± 33 103 ± 31 96 ± 3 2 79 ± 28 <0.01
 Urinary protein excretion, mg/day 78 (54–116) 90 (69–130) 92 (65–132) 108 (70–172) <0.01
 Glucose, mg/dl 97 ± 25 103 ± 33 102 ± 26 104 ± 35 0.20
 Insulin, µUI/ml 8.10 (5.35–11.80) 9.50 (5.90–12.80) 9.75 (6.28–14.23) 9.30 (6.40–13.00) 0.12
 HOMA index 1.88 (1.18–2.90) 2.21 (1.32–3.25) 2.24 (1.53–3.31) 2.18 (1.41–3.70) 0.10
 AUC-G, mg/dl/min 393 ± 110 398 ± 114 393 ± 85 406 ± 121 0.85
 AUC-I, µUI/ml/min 176 (124–300) 168 (97–297) 180 (121–275) 195 (128–344) 0.66
 Triglycerides, mg/dl 92 (71–125) 107 (80–150) 113 (82–159) 111 (85–160) <0.01
 Total cholesterol, mg/dl 203 ± 37 213 ± 48 205 ± 38 202 ± 44 0.14
 HDL cholesterol, mg/dl 59 ± 16 59 ± 18 55 ± 15 56 ± 15 0.08
 LDL cholesterol, mg/dl 122 ± 36 125 ± 36 123 ± 36 119 ± 38 0.54
 Uric acid, mg/dl 5.25 ± 1.40 5.49 ± 1.43 5.66 ± 1.47 6.00 ± 1.65 <0.01
 Homocysteine, µmol/l 8.1 (7.3–8.8) 10.5 (10.0–11.2) 13.4 (12.5–14.0) 17.5 (15.8–20.7) <0.01
 Vitamin B12, pg/ml 427 (318–531) 383 (305–517) 392 (294–511) 356 (256–467) 0.03
 Folate, ng/ml 5.90 (4.10–8.25) 5.58 (4.05–7.90) 5.30 (3.50–6.49) 4.20 (3.00–5.40) <0.01
 Fibrinogen, mg/dl 350 (303–402) 360 (305–409) 350 (311–396) 369 (323–432) 0.02
Values are expressed as mean ± SD. Median and interquartile range given in parenthesis under “Biochemical variables” are shown for vari-
ables with skewed distribution. Comparisons among homocysteine quartiles were done by analysis of variance with the post hoc Bonferroni test 
used to correct for multiple comparisons. Pearson’s chi-square test was used to compare frequency distributions. To convert to international 
units, multiply creatinine by 88.4 (µmol/l), glucose by 0.05551 (nmol/l), insulin by 7.175 (pmol/l), cholesterol by 0.0259 (mmol/l), triglycerides by 
0.0113 (mmol/l), and uric acid by 59.485 (µmol/l).
Abbreviations: AUC-G, area under the curve of plasma glucose after oral glucose tolerance test; AUC-I, area under the curve of plasma 
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with the post hoc Bonferroni test used to correct for mul-
tiple comparisons. Pearson’s chi-square test was used to 
compare frequency distributions. Relationship between con-
tinuous variables was examined through linear regression 
analysis, with correlation expressed by Pearson’s correlation 
coefficient.
Multivariate logistic regression analysis was used to assess 
independence of association of plasma Hcy levels that were 
treated as the primary independent variable with metabolic 
syndrome that was the dependent variable. In a separate 
model, we assessed independence of association of Hcy 
levels that were the independent variable with cardiovas-
cular events that were the dependent variable, with subse-
quent inclusion in the model of the metabolic syndrome. 
Data analyses were done with the Stata 9.2 software system 
(StataCorp LP, College Station, TX).
RESULTS
The demographic and clinical characteristics of the study 
patients are summarized in Table 1, where patients are also 
divided according to the presence or absence of the meta-
bolic syndrome. The prevalence of the metabolic syndrome 
in the entire hypertensive group was 36.7% and the preva-
lence of CHD (angina: 41 patients; acute coronary syn-
drome: 34 patients; coronary revascularization: 28 patients) 
and CVD (stroke: 16 patients; transient ischemic attack: 
18 patients) was 9.6% and 4.8%, respectively. Male sex was 
more prevalent among patients with the metabolic syn-
drome who were also older, more often diabetics, smokers, 
and more frequently treated with antihypertensive agents, 
had greater body mass index and waist circumference, and 
had longer duration of hypertension than patients without 
the metabolic syndrome. No significant differences in prev-
alence of CHD and CVD were observed between patients 
with or without the metabolic syndrome. In addition to 
higher fasting plasma glucose, triglycerides, and insulin, 
HOMA index, and plasma glucose and insulin responses to 
OGTT, hypertensive patients with the metabolic syndrome 
had lower high-density lipoprotein cholesterol, higher Hcy 
and fibrinogen levels, and worse renal function with greater 
urinary protein losses than patients without the metabolic 
syndrome.
Table  2 shows the demographic and clinical character-
istics of the study patients who were divided into quartiles 
of Hcy levels. Age, frequency of male sex, antihypertensive 
treatment, and prevalence of the metabolic syndrome and 
both CHD and CVD increased progressively with increas-
ing plasma Hcy. Combined prevalence of CHD and CVD 
increased progressively across quartiles of plasma Hcy lev-
els with no significant differences between patients with or 
without the metabolic syndrome (Figure 1). Increasing Hcy 
levels were also associated with increasing plasma triglycer-
ides and uric acid levels, decreasing vitamin B12 and folate, 
and progressively worse renal function with greater urinary 
protein excretion, whereas no differences were observed 
in other plasma lipids, fasting plasma glucose and insulin, 
HOMA index, glucose and insulin response to OGTT, and 
fibrinogen levels (Table  2). The number of patients who 
required use of calcium channel blockers during the wash-
out period did not differ across quartiles of plasma Hcy.
On univariate regression analysis, Hcy was significantly 
and directly related with age, waist circumference, fasting 
glucose, triglycerides, uric acid, and fibrinogen levels, and 
HOMA index and inversely related with creatinine clear-
ance and high-density lipoprotein cholesterol, vitamin B12, 
Table 3. Univariate correlation analysis with plasma 
homocysteine level as the dependent variable
 Variables r P
Age, year 0.190 <0.01
Body mass index, kg/m2 −0.028 0.51
Waist circumference, cm 0.110 0.02
Systolic blood pressure, mm Hg 0.056 0.19
Diastolic blood pressure, mm Hg −0.010 0.81
Duration of hypertension, year 0.065 0.14
Alcohol intake, g/day 0.017 0.68
Creatinine clearance, ml/min/1.73 m2 −0.181 <0.01
Glucose, mg/dl 0.096 0.02
Insulin, µUI/ml 0.090 0.05
HOMA index 0.098 0.04
AUC-G, mg/dl/min 0.028 0.61
AUC-I, µUI/ml/min −0.003 0.96
Triglycerides, mg/dl 0.127 <0.01
Total cholesterol, mg/dl −0.017 0.69
HDL cholesterol, mg/dl −0.094 0.03
LDL cholesterol, mg/dl −0.005 0.73
Uric acid, mg/dl 0.190 <0.01
Vitamin B12, pg/ml −0.186 <0.01
Folate, ng/ml −0.240 <0.01
Fibrinogen, mg/dl 0.093 0.03
Abbreviations: AUC-G, area under the curve of plasma glucose 
after oral glucose tolerance test; AUC-I, area under the curve of 
plasma insulin after oral glucose tolerance test; HDL, high-density 
lipoprotein; HOMA, homeostatic model assessment; LDL, low-den-
sity lipoprotein.
Figure  1. Prevalence of coronary heart and cerebrovascular disease 
according to quartiles of plasma homocysteine levels in hypertensive 
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and folate levels (Table  3). In a logistic regression analysis 
that included the metabolic syndrome as the dependent 
variable and Hcy as the primary independent variable, Hcy 
was associated with the presence of the metabolic syndrome 
independent of demographic and anthropometric variables, 
duration of hypertension, antihypertensive treatment, and 
additional variables that were related with Hcy on univari-
ate regression analysis (Table 4). In a further logistic regres-
sion model that included cardiovascular events (CHD and 
CVD) as the dependent variable and adjusted for the same 
confounders, Hcy was associated with the presence of events 
independent of other confounders (Table  4). Independent 
relationship of Hcy with cerebro-cardiovascular disease per-
sisted significant after inclusion of metabolic syndrome in 
the logistic model (P = 0.01).
DISCUSSION
The findings of this study demonstrate that elevated 
plasma Hcy levels are associated with greater prevalence 
of the metabolic syndrome in hypertensive patients. This 
association is independent of demographic and anthropo-
metric variables, duration of hypertension, renal function, 
and plasma levels of vitamin B12, folate, and inflammatory 
markers. Moreover, increasing Hcy levels are associated with 
progressively greater prevalence of both CHD and CVD, 
although no interaction between Hcy and the metabolic 
syndrome was observed for this association, suggesting that 
the impact of Hcy on cerebro-cardiovascular disease is inde-
pendent of the metabolic syndrome in these patients.
Both the metabolic syndrome and elevated plasma Hcy 
are established independent risk factors for cardiovascular 
events in the general population1,2,7,8 and both animal10 and 
human13 studies have suggested that hyperhomocysteinemia 
might be an integral component of the metabolic syndrome. 
Findings previously obtained in the general population on 
the association between Hcy and the metabolic syndrome 
were highly controversial11–13,27–30 and also studies con-
ducted in special populations such as adolescents31 and 
patients with obesity32 or CHD33 did not provide consistent 
findings. On the other hand, investigations that have looked 
for an association of Hcy levels with insulin resistance either 
in the general population34,35 or in special groups of patients 
such as women with the polycystic ovary syndrome36 or psy-
chiatric disorders37 reported a significant association that 
was not confirmed in other studies conducted in the general 
population38,39 and subjects predisposed to type-2 diabetes.40 
Many factors could account for these substantial discrepan-
cies including age of patients, ethnic differences, methods 
used to assess insulin sensitivity, and the limited sample size 
of some of these studies.
Elevated fasting plasma Hcy levels have been reported 
in hypertensive patients of different age and ethnicity.14–16 
However, only 2 studies were specifically designed to inves-
tigate the relationship of plasma Hcy with insulin resistance 
and the metabolic syndrome in hypertensives, an issue that 
could be relevant because of the high cardiovascular risk of 
these patients. Sheu et al.14 reported that plasma levels of Hcy 
are higher in Chinese hypertensive subjects than matched 
normotensive controls. They also found a significant 
Table 4. Multivariate logistic regression analysis was performed to assess independence of association with plasma homocysteine levels
Model 1 Model 2
Variables Odds ratio CI P Odds ratio CI P
Age 1.002 0.96–1.05 0.94 1.056 1.00–1.12 0.05
Male sex 0.070 0.02–0.26 <0.01 2.053 0.48–8.85 0.33
Waist circumference 1.136 1.07–1.20 <0.01 1.027 0.97–1.09 0.36
Duration of hypertension 0.984 0.93–1.04 0.54 1.037 0.98–1.10 0.23
Creatinine clearance 1.010 0.99–1.03 0.36 0.999 0.98–1.02 0.91
Glucose 1.096 1.05–1.14 <0.01 1.005 0.98–1.03 0.74
HOMA index 0.999 0.99–1.00 0.55 0.998 0.99–1.00 0.10
Triglycerides 1.008 1.00–1.01 <0.01 0.999 0.99–1.00 0.43
HDL cholesterol 0.954 0.92–0.99 <0.001 0.983 0.94–1.03 0.45
Homocysteine 1.010 1.00–1.02 0.02 1.011 1.00–1.02 0.01
Vitamin B12 1.002 1.00–1.03 <0.01 1.000 0.99–1.02 0.86
Folate 1.001 1.00–1.02 0.27 1.001 0.99–1.03 0.34
Uric acid 1.021 0.98–1.06 0.31 0.985 0.94–1.03 0.52
Fibrinogen 1.000 0.99–1.00 0.90 1.001 1.00–1.01 0.81
In a first model (Model 1), metabolic syndrome was treated as the dependent variable and plasma homocysteine levels as the primary 
independent variable, showing that association of metabolic syndrome with homocysteine levels is independent of confounders adjusted in the 
model. In a second model (Model 2), cerebro-cardiovascular disease was treated as the dependent variable and plasma homocysteine levels 
as the primary independent variable, showing that association of cerebro-cardiovascular disease with homocysteine levels is independent of 
confounders adjusted in the model.
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correlation of plasma Hcy with post-OGTT insulin levels, 
but not with markers of insulin resistance. Ustundag et al.16 
examined 114 Turkish patients with uncomplicated hyper-
tension and plasma Hcy levels higher than those of normo-
tensive controls and reported significantly higher Hcy levels 
in patients with insulin resistance as defined by a HOMA 
index of 4 or more. The present study was conducted in a 
much larger cohort of hypertensive patients and demon-
strates that elevated plasma Hcy has a highly significant 
association with the metabolic syndrome that is independ-
ent of factors that may affect Hcy levels such as age, smok-
ing habit, and, most important, renal function and vitamin 
B12 and folate levels. Furthermore, Hcy levels are associated 
with higher prevalence of CHD and CVD. Relevant to this 
point, however, we did not observe a significant interaction 
between Hcy and the metabolic syndrome, suggesting an 
independent contribution of Hcy to the cardiovascular out-
come of hypertensive patients.
The present study has limitations that should be consid-
ered. First, use of a clinical sample might limit the possibil-
ity to extend findings to a more general context, because of a 
possible bias in the referral of patients to the source of care. 
Second, the cross-sectional design does not permit to draw 
any conclusion on a causal relationship between elevated Hcy 
levels and incidence of CHD and CVD. Also, a tight control of 
cardiovascular risk factors in these patients that were followed 
in our tertiary center could explain the relatively small pro-
portion of patients who had cerebro-cardiovascular disease, 
a fact that might have limited the strength of some associa-
tions. This might also explain why we did not observe sig-
nificant differences in prevalence of CHD and CVD between 
patients with or without the metabolic syndrome. Third, 
inclusion of a relevant number of hypertensive patients who 
were not treatment-naive might have introduced, despite a 
relatively long wash-out period, a possible confounder affect-
ing some of the metabolic variables measured in this study. It 
must be noticed, however, that no significant differences in 
these metabolic variables were observed between untreated 
patients and patients who were treated with different types 
of antihypertensive drugs. Fourth, although plasma levels of 
vitamin B12 and folate were measured in all patients and were 
included together with other possible confounders in the sta-
tistical analysis, use of a questionnaire providing information 
on the dietary intake of food containing these vitamins or 
metabolic precursors of Hcy and genotyping of patients for 
methylenetetrahydrofolate reductase would have helped in 
the interpretation of data. Last, we did not measure the levels 
of glycated hemoglobin in nondiabetic patients which also 
might have helped to better define the glicometabolic status 
of our hypertensive patients.
In conclusion, this study demonstrates in a large group 
of hypertensive patients that elevated plasma Hcy levels are 
associated with the presence of the metabolic syndrome 
independent of all major factors involved in regulation of 
circulating Hcy. Also, elevated Hcy is associated with greater 
prevalence of cerebro-cardiovascular disease. These obser-
vations could be relevant for the assessment of the cardiovas-
cular risk in hypertensive patients and for their management 
because detection of high Hcy levels might guide physicians 
towards better control of additional metabolic risk factors. 
Also, vitamin supplementation in hypertensive patients with 
elevated Hcy levels might result beneficial for cardiovascular 
protection of these patients, but this possibility will have to 
be tested in future studies.
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